1 active not recruiting, 1 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Trabedersen: new trials by email Literature Review of Trabedersen trials Research Report on Trabedersen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 Trabedersen, Pembrolizumab - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | University of Nebraska | 45 | 2025-05-12 | 2026-09-25 |
| Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 AP 12009 - Pancreatic Neoplasms, Melanoma | Phase 1 | Completed | Isarna Therapeutics GmbH | 62 | 2005-01-01 | 2019-02-15 |
Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Melanoma (1) · Pancreatic Neoplasms (1)
Isarna Therapeutics GmbH (1) · University of Nebraska (1)
Germany (1) · United States (1)
Helmut Oettle, MD (1) · Omar Abughanimeh, MBBS (1)